atropine has been researched along with montelukast in 9 studies
| Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) | Studies (montelukast) | Trials (montelukast) | Recent Studies (post-2010) (montelukast) |
|---|---|---|---|---|---|
| 26,711 | 1,259 | 1,697 | 1,965 | 598 | 777 |
| Protein | Taxonomy | atropine (IC50) | montelukast (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 3.197 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 4.702 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 3.488 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.689 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 3.919 | |
| Adenosine receptor A3 | Homo sapiens (human) | 0.434 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 0.7 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 8.045 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 4.3 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.434 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 5.279 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 6.626 | |
| Substance-K receptor | Homo sapiens (human) | 3.822 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.689 | |
| Thromboxane-A synthase | Homo sapiens (human) | 1.525 | |
| D(3) dopamine receptor | Homo sapiens (human) | 7.747 | |
| Delta-type opioid receptor | Homo sapiens (human) | 4.795 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 6.256 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.434 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.601 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.856 | |
| Leukotriene C4 synthase | Homo sapiens (human) | 5 | |
| Cysteinyl leukotriene receptor 1 | Homo sapiens (human) | 0.0015 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Hiyama, Y; Ishimura, M; Kataoka, S; Maeda, T; Suda, M | 1 |
| Chang, BS; Chang, JC; Huang, SC; Wang, YS | 1 |
1 review(s) available for atropine and montelukast
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for atropine and montelukast
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetates; Acetylcholine; Albuterol; Animals; Atropine; Benzoquinones; Carbachol; Chromones; Cyclopropanes; Dinoprost; Drug Evaluation, Preclinical; Guinea Pigs; Heptanoic Acids; Histamine; In Vitro Techniques; Indoles; Indomethacin; Ketanserin; Ketotifen; Leukotriene Antagonists; Leukotriene D4; Male; Muscle Contraction; Muscle, Smooth; Phenylcarbamates; Powders; Procaterol; Prostaglandin Antagonists; Prostaglandin D2; Quinolines; Receptors, Thromboxane A2, Prostaglandin H2; Serotonin; Substance P; Sulfides; Sulfonamides; Tosyl Compounds; Trachea; Tryptophan | 2006 |
Cysteinyl leucotriene receptor type 1 mediates contraction in human and guinea-pig oesophagus.
Topics: Acetates; Animals; Atropine; Capsaicin; Carbachol; Cholinergic Agonists; Cyclopropanes; Esophagus; Guinea Pigs; Humans; Indoles; Leukotriene Antagonists; Leukotrienes; Male; Muscarinic Antagonists; Muscle Contraction; Phenylcarbamates; Quinolines; Receptors, Leukotriene; Sensory System Agents; Sodium Channel Blockers; SRS-A; Sulfides; Sulfonamides; Tetrodotoxin; Tosyl Compounds | 2008 |